The effect of paroxetine on the quantitative EEG

McClelland, G.R.; Raptopoulos, P.; Jackson, D.

doi:10.1111/j.1600-0447.1989.tb07173.x

Cited by 21 publications

(5 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Knott et al 108 described QEEG changes after acute and chronic (6 weeks) paroxetine administration (20 mg/day) in drug-free unipolar depressed patients. At odds with investigations carried out in healthy subjects, 105,106 in the acute study paroxetine could not be discriminated from placebo. After 6 weeks of treatment, paroxetine-induced changes were similar to those reported for sedative antidepressant drugs.…”

Section: Prediction Of Clinical Response To Treatment With Psychotropic Drugsmentioning

confidence: 64%

See 1 more Smart Citation

Pharmaco-EEG in Psychiatry

et al. 2006

View full text Add to dashboard Cite

In spite of its origins deeply rooted in the discipline, pharmaco-EEG applications in psychiatry remain limited to its achievements in the field of psychotropic drugs classification and, in few instances, discovery. In the present paper two attempts to transfer pharmaco-EEG methods to psychiatric clinical routine will be described: 1) monitoring of psychotropic drug toxicity at the central nervous system level, and 2) prediction of clinical response to treatment with psychotropic drugs. Both applications have been the object of several investigations providing promising and sometimes consistent findings which, however, had no impact on clinical practice. For the first topic, the review is limited to antipsychotics, lithium and recreational drugs, as for other psychotropic drugs mostly case studies are available, while for the response prediction it will include antipsychotics, antidepressants, anxiolytics, psychostimulants and nootropics. In spite of several methodological limitations, pharmaco-EEG studies dealing with monitoring of antipsychotic- and lithium-induced EEG abnormalities went close to, but never became, a clinical routine. EEG studies of recreational drugs are flawed by several limitations, and failed, so far, to identify reliable indices of CNS toxicity to be used in clinical settings. Several QEEG studies on early predictors of treatment response to first generation antipsychotics have produced consistent findings, but had no clinical impact. For other psychotropic drug classes few and inconsistent reports have appeared. Pharmaco-EEG had the potential for important clinical applications, but so far none of them entered clinical routine. The ability to upgrade theories and methods and promote large scale studies represent the future challenge.

show abstract

Section: Prediction Of Clinical Response To Treatment With Psychotropic Drugsmentioning

confidence: 64%

“…Paroxetine 30 mg induced QEEG changes are similar to those induced by amitriptyline, while paroxetine 70 mg showed a profile close to the desipramine one. 105,106…”

Section: Prediction Of Clinical Response To Treatment With Psychotropic Drugsmentioning

confidence: 99%

Pharmaco-EEG in Psychiatry

et al. 2006

View full text Add to dashboard Cite

show abstract

“…A single dose of 30 mg paroxetine also produced changes comparable with those induced by amitriptyline, with fewer sedative properties as demonstrated by the lack of detrimental effects on objective measurements of cognitive functions in humans with a single or multiple dose regimen [23,24]. In contrast, a higher dose of 70 mg of paroxetine produced greater EEG activation with a decrease in slow waves and an increase in beta activities [25]. A single dose of sertraline induced EEG changes consistent with alertness or vigilance-enhancing properties in a dose of 100 mg and more suggestive of sedative effects in higher doses of 200 to 400 mg [17,26,27].…”

Section: Eegmentioning

confidence: 91%

EEG profile of litoxetine after single and repeated administration in healthy volunteers.

Patat¹,

Trocherie²,

Thebault³

et al. 1994

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Litoxetine is a selective serotonin reuptake inhibitor with antidepressant activity in animal models and in depressed patients. 2 This double-blind, cross-over, placebo-controlled study was carried out in 12 healthy young male volunteers. The aim was to assess the EEG profile of litoxetine in parallel with its pharmacokinetics after a single dose or multiple administrations for 4 days (6 doses) of two dosages (10 mg and 25 mg). Spectral analysis of four EEG leads (F4-T4, F3-T3, T4-02 and T3-01) was done up to 12 h post-dose. 3 In single or multiple doses, litoxetine induced EEG changes characterised by a doserelated increase in fast beta energies, mainly beta 2, without any changes in slow waves (delta and theta). A slight reduction in alpha activity occurred only after repeated doses. 4 EEG changes occurred after a single oral administration and lasted at least 12 h with litoxetine blood concentrations ranging from 4 to 10 ng ml-'. With repeated administrations, the pharmacodynamic steady-state was achieved as the increase in beta 2 energies was the same before and 12 h post-dose. These effects occurred with litoxetine blood concentrations ranging from 3 to 7 ng ml-1 with the 10 mg dosage and from 8 to 18 ng ml-1 with the 25 mg dosage. The EEG profile did not change after 4 days of repeated administration, indicating that tolerance did not develop. 5 Cmax and AUC showed proportionality between the administered dosages of 10 and 25 mg. Mean tmax ranged from 3 to 4 h and mean elimination half-life from 7 to 9 h independently of the dosage. Pharmacokinetic steady-state was achieved on day 4. Litoxetine did not accumulate with a twice daily regimen. 6 In conclusion, the EEG profile of litoxetine resembles those previously described with non-sedative antidepressants. Such EEG changes generally occur at therapeutic dosages.

show abstract

“…151 Numerous QEEG studies have found increased alpha and/or theta power in a high percentage of depressed patients. 8,19,[152][153][154][155][156][157] Antidepressants reduce alpha activity, 153,[158][159][160][161] suggesting normalization of these deviant QEEG features (in contrast to the increased alpha caused by neuroleptics). [113][114][115] Interhemispheric asymmetry, especially in anterior regions, has been reported repeatedly, [162][163][164][165][166] as has decreased coherence.…”

Section: Mood Disorders: Unipolar and Bipolar Depressionmentioning

confidence: 99%

Conventional and Quantitative Electroencephalography in Psychiatry

Hughes¹,

John²

1999

JNP

408

296

View full text Add to dashboard Cite

Electrical activity of each brain region is homeostatically regulated, resulting in predictable frequency composition of the background EEG. Replicated normative databases have established that the EEG power spectrum is independent of ethnic background. Artifact-free EEG evaluated relative to such norms displays few deviant values in healthy, normally functioning individuals. In subjects with psychiatric disorders, high proportions of abnormal findings have been reported with good concordance and high specificity and sensitivity across numerous studies, distinctive within a wide variety of disorders and often contributing to differential diagnosis and selection of treatment. New three-dimensional QEEG imaging methods offer an economical alternative to other functional brain imaging modalities.

show abstract

The effect of paroxetine on the quantitative EEG

Cited by 21 publications

References 6 publications

Pharmaco-EEG in Psychiatry

Pharmaco-EEG in Psychiatry

EEG profile of litoxetine after single and repeated administration in healthy volunteers.

Conventional and Quantitative Electroencephalography in Psychiatry

Contact Info

Product

Resources

About